INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol.62, no.9, 2021 (SCI-Expanded)
PURPOSE. To determine the effect of the new beta(3)-agonist (mirabegron), which is used for overactive bladder (OAB) treatment, on central retinal thickness (CRT) and choroidal vascularity.